Last Updated : May 14, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
Brand Name | Generic Name | Therapeutic Area Sort ascending | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
---|---|---|---|---|---|---|
Brilinta | Ticagrelor | Acute Coronary Syndromes | Cancelled | |||
Brilinta | Ticagrelor | Acute coronary syndromes | Do not list | Complete | ||
Effient | Prasugrel | Acute coronary syndrome | Do not list | Complete | ||
Effient | Prasugrel hydrochloride | Acute Coronary Syndrome | Do not list | Complete | ||
Sivextro | Tedizolid phosphate | Acute bacterial skin and skin structure infections | Withdrawn | |||
Xydalba | dalbavancin | Acute bacterial skin and skin structure infections | Reimburse with clinical criteria and/or conditions | Complete | ||
TBC | leniolisib | Activated phosphoinositide 3 kinase delta syndrome | Active | |||
Picato | Ingenol mebutate | Actinic keratosis | Do not list | Complete | ||
Picato | Ingenol mebutate | Actinic keratosis | N/A | Complete | ||
Somavert | Pegvisomant | acromegaly | Do not list | Complete |